| Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20841518 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus. DATA SOURCES: A MEDLINE search (1966-May 2010) was conducted for English-language, human studies using the terms mitiglinide, KAD 1229, S 21403, and meglitinide analogs. Abstracts presented at the American Association and European Association for the Study of Diabetes annual meetings from 2005 to 2009 were also evaluated for relevant data. STUDY SELECTION AND DATA EXTRACTION: Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide were reviewed. DATA SYNTHESIS: Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A(1c), postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. Mitiglinide exerts its hypoglycemic activity by closing adenosine triphosphate (ATP)-sensitive potassium channels in the β-islet cells of the pancreas. This agent has a rapid onset and short duration of action, mimicking a physiologic pattern of insulin release in nondiabetic people. Studies suggest a starting dose of 5 mg 3 times daily with meals and a maximum dose of 20 mg 3 times daily. Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia. CONCLUSIONS: Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies. |
| | |
Authors:
|
Haley M Phillippe; Kurt A Wargo |
Related Documents
:
|
16356228 - Intensive insulin therapy does not alter the inflammatory response in patients undergoi... 16984828 - Update on drugs used to treat endocrine diseases in small animals. 12643338 - Slow response to loss of glycemic control in type 2 diabetes mellitus. 6794018 - Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. 14991848 - Glucose deprivation increases hydrogen peroxide level in immunostimulated rat primary a... 12586768 - Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-09-14 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 44 ISSN: 1542-6270 ISO Abbreviation: Ann Pharmacother Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-23 Completed Date: 2011-01-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1615-23 Citation Subset: IM |
Affiliation:
|
Auburn University, AL, USA. mccrahl@auburn.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Diabetes Mellitus, Type 2 / drug therapy* Humans Hypoglycemic Agents / pharmacokinetics, pharmacology, therapeutic use* Isoindoles / pharmacokinetics, pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Isoindoles; 0/mitiglinide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The impact of continuing professional development versus traditional continuing pharmacy education o...
Next Document: Acute generalized exanthematous pustulosis as a manifestation of anticonvulsant hypersensitivity syn...